Redeye gives its initial take on BONESUPPORT’s Q3 report. With a slight miss to our estimates on both sales and EBIT (and to consensus), we believe the market’s short-sightedness will not appreciate the reported figures. However, upon closer examination, we see a strong free cash flow and a rapidly accumulating cash position for a company with continued untapped potential, both in its extremities and its impending launch into spine. Still, we expect the share to trade in the negatives today, of about -3-5%
LÄS MER
